45 Results for "

integrin signaling

" in MedChemExpress (MCE) Product Catalog:
Products (45)

45 Results for "integrin signaling" in MCE Product Catalog:

74
74 Publications Verification
Cat. No.: HY-16141
CAS No.: 188968-51-6
Synonyms: EMD 121974
Cilengitide (EMD 121974) is a BBB-permeable integrins antagonist with IC50s of 0.61 nM (ανβ3), 8.4 nM (ανβ5) and 14.9 nM (α5β1), respectively. Cilengitide inhibits the binding of ανβ3 and ανβ5 to Vitronectin with IC50s of 4 nM and 79 nM, respectively. Cilengitide inhibits TGF-β/Smad signaling, mediates PD-L1 expression. Cilengitide also induces apoptosis, shows antiangiogenic effect in the research against glioblastoma and other cancers .
loading...
    loading...
12
12 Cited Publications
Cat. No.: HY-18676
CAS No.: 2070015-22-2
Research Areas:  

Cancer

OSU-T315 (ILK-IN-1) is a small Integrin-linked kinase (ILK) inhibitor with an IC50 of 0.6 μM, inhibiting PI3K/AKT signaling by dephosphorylation of AKT-Ser473 and other ILK targets (GSK-3β and myosin light chain) . OSU-T315 abrogates AKT activation by impeding AKT localization in lipid rafts and triggers caspase-dependent apoptosis in an ILK-independent manner . OSU-T315 causes cell death through apoptosis and autophagy .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-13306
CAS No.: 1228445-38-2
Purity:  99.71%
Target:  

Integrin

Research Areas:  

Metabolic Disease

Pyrintegrin is an β1-integrin agonist and a 2,4-disubstituted pyrimidine that promotes embryonic stem cells survival. Pyrintegrin enhances cell-extracellular matrix (ECM) adhesion-mediated integrin signaling. Pyrintegrin can be used as a podocyte-protective agent and has robustly adipogenic .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-15701
CAS No.: 344897-95-6
Purity:  ≥98.0%
Research Areas:  

Inflammation/Immunology

Leukadherin-1, a specific agonist of the leukocyte surface integrin CD11b/CD18, increases CD11b/CD18-dependent cell adhesion to fibrinogen with an EC50 of 4 μM. Leukadherin-1 enhances leukocyte adhesion to ligands (such as ICAM-1) and vascular endothelium and thus reduces leukocyte transendothelial migration and influx to the injury sites. Leukadherin-1 suppresses innate inflammatory signaling .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P1408
CAS No.: 404882-00-4
Target:  

Integrin VEGFR

Research Areas:  

Cancer

Obtustatin is a non-RGD disintegrin consisting of 41 residues. Obtustatin inhibits the adhesion of α1β1 integrin to type IV Collagen (HY-NP003), blocks α1β1 integrin signaling in endothelial cells, and suppresses FGF2-induced angiogenesis. Obtustatin inhibits tumor progression in mouse models and upregulates VEGF expression in sarcoma-bearing mice. Obtustatin can be used in research related to Lewis lung carcinoma and S-180 sarcoma .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1868
CAS No.: 134580-64-6
Synonyms: DGEA peptide
Target:  

Integrin

Research Areas:  

Infection

α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P1868A
Synonyms: DGEA peptide TFA
Target:  

Integrin

Research Areas:  

Others

α2β1 Integrin Ligand Peptide TFA interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. It is a potential antagonist of collagen receptors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P5133
CAS No.: 1259384-47-8
Synonyms: SSTN92-119
Target:  

Integrin

Research Areas:  

Cancer

Synstatin (92-119) is an inhibitor of αvβ3/αvβ5 integrins and IGF1R with anti-angiogenic, anti-proliferative, antioxidant and anti-tumor activities. Synstatin (92-119) competitively blocks the capture of αvβ3/αvβ5 integrins and IGF1R by syndecan-1, disrupts the formation of the syndecan-1 : integrin : IGF1R ternary complex, inhibits integrin activation and talin-mediated signaling pathways, and blocks VEGF-induced angiogenesis. Synstatin (92-119) is applicable to research related to cancer and hepatocellular carcinoma .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P0204A
Synonyms: Endothelin 3 (Rat,Human) TFA
Research Areas:  

Neurological Disease

Endothelin-3, human, mouse, rabbit, rat TFA (Endothelin 3 (Rat,Human) TFA) is an adhesion stimulant. Endothelin-3, human, mouse, rabbit, rat TFA stimulates the adhesion of enteric neural crest cells to various ECM components. Endothelin-3, human, mouse, rabbit, rat TFA plays an important role in the maintenance and self-renewal of intestinal progenitor cells, participates in the migration of enteric neural crest cells, and helps maintain a suitable environment for the colonization of enteric neural crest cells. Endothelin-3, human, mouse, rabbit, rat TFA acts synergistically with the β1-integrin signaling pathway during enteric nervous system development. Endothelin-3, human, mouse, rabbit, rat TFA can be used in studies related to distal aganglionosis .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P0204
CAS No.: 117399-93-6
Synonyms: Endothelin 3 (Rat,Human)
Research Areas:  

Neurological Disease

Endothelin-3, human, mouse, rabbit, rat (Endothelin 3 (Rat,Human)) is an adhesion stimulant. Endothelin-3, human, mouse, rabbit, rat stimulates the adhesion of enteric neural crest cells to various ECM components. Endothelin-3, human, mouse, rabbit, rat plays an important role in the maintenance and self-renewal of intestinal progenitor cells, participates in the migration of enteric neural crest cells, and helps maintain a suitable environment for the colonization of enteric neural crest cells. Endothelin-3, human, mouse, rabbit, rat acts synergistically with the β1-integrin signaling pathway during enteric nervous system development. Endothelin-3, human, mouse, rabbit, rat can be used in studies related to distal aganglionosis .
loading...
    loading...
Cat. No.: HY-149136
CAS No.: 2412688-16-3
Target:  

Integrin TGF-beta/Smad

Research Areas:  

Inflammation/Immunology

MORF-627 is a highly selective, orally active integrin αvβ6 inhibitor. By blocking TGF-β1 activation and pSMAD2 signaling, MORF-627 significantly reduces collagen deposition, epithelial-mesenchymal transition markers, and structural changes in fibrotic cells. MORF-627 exhibits significant antifibrotic efficacy without genotoxicity in idiopathic pulmonary fibrosis models. However, MORF-627 induces bladder epithelial proliferation and early invasive urothelial carcinoma in cynomolgus monkeys and human cells, and this toxic effect can be reversed by exogenous TGF-β. MORF-627 can be used for studying the pathological mechanisms of pulmonary fibrosis and evaluating drug safety .
loading...
    loading...
Cat. No.: HY-P11328
CAS No.: 245120-10-9
Target:  

Integrin

Research Areas:  

Others

GFOGER peptide is an artificially synthesized collagen-mimetic sequence. GFOGER peptide acts as a ligand for α2β1, α11β1 and α1β1 integrins, thereby supporting integrin-mediated cell adhesion to collagen. GFOGER peptide triggers signaling pathways mediated by the α2β1 integrin receptor and upregulates osteoblast differentiation. GFOGER peptide accelerates and enhances bone formation at sites of refractory femoral defects. GFOGER peptide can be passively adsorbed onto polymer scaffolds for cell-free/growth factor-free bone formation. GFOGER peptide is used in biomaterials such as hydrogels and 3D bioinks for tissue engineering research including bone formation .
loading...
    loading...
Cat. No.: HY-P99296
CAS No.: 725735-28-4
Synonyms: CNTO 95; Anti-Human CD51 Recombinant Antibody

Target:  

Integrin Apoptosis

Research Areas:  

Cancer

Intetumumab (CNTO 95) is a human monoclonal antibody targeting αv integrin, with a Kd value of 1-24 nM. Through high-affinity binding to αv integrin, Intetumumab inhibits its interaction with extracellular matrix proteins (such as vitronectin and fibronectin), thereby blocking the downstream focal adhesion kinase signaling pathway. This further inhibits the adhesion, migration and invasion of tumor cells as well as the proliferation of vascular endothelial cells, promotes cell apoptosis, and exerts anti-tumor and anti-angiogenic effects. Intetumumab can be used in research related to head and neck cancer, non-small cell lung cancer and uterine serous papillary carcinoma .
loading...
    loading...
Cat. No.: HY-148385
CAS No.: 127663-77-8
Purity:  98.0%
Ganglioside GM2 is a human tumor antigen predominantly found in human tumor cells and fetal brain tissue. As a sialylated glycosphingolipid, Ganglioside GM2 is involved in processes such as cell signaling, adhesion, and motility. Ganglioside GM2 abnormal expression and accumulation are associated with tumors and neurodegenerative disorders. Ganglioside GM2 promotes tumor cell migration and invasion by directly binding to the integrin β1 receptor, activating the FAK/Src/Erk-MAPK signaling pathway, and inducing actin cytoskeleton remodeling .
loading...
    loading...
Cat. No.: HY-173496
CAS No.: 192876-13-4
Research Areas:  

Cancer

ST6GAL1-IN-1 is an orally active selective ST6GAL1 inhibitor (IC50 = 20 μM). ST6GAL1-IN-1 exhibits high antimetastatic potential, effectively inhibiting the migration of MDA-MB-231 cells at noncytotoxic concentrations. ST6GAL1-IN-1 can disrupt integrin sialylation in MDA-MB-231 cells. ST6GAL1-IN-1 inhibits tumor angiogenesis and cancer metastasis via the Integrin/VEGFR2-mediated signaling pathway. ST6GAL1-IN-1 effectively suppresses both tumor growth and cancer metastasis on the MDA-MB-231 xenograft model. ST6GAL1-IN-1 can be used for the study of Triple-negative breast cancer (TNBC) .
loading...
    loading...
Cat. No.: HY-P99524
CAS No.: 1238217-55-4
Synonyms: GBR500

Target:  

Integrin

Vatelizumab (GBR500) is a monoclonal antibody that targets the α2 subunit (CD49b) of very late antigen 2 (VLA-2). Vatelizumab can be used for research on multiple sclerosis .
loading...
    loading...
Cat. No.: HY-120548
CAS No.: 1143863-69-7
Purity:  99.52%
Research Areas:  

Cancer

KBU2046 is an orally active transforming growth factor-β (TGF-β1) inhibitor. KBU2046 reduces integrin family protein expression, decreases Raf, RIPK1 and ERK phosphorylation to deactivate the ERK signaling pathway, and down-regulates genes linked to TGF-β1 maturation. KBU2046 suppresses tumor cell motility, impedes cancer invasion and metastasis, and inhibits human ESCC growth and metastasis in a murine model. KBU2046 can be used for the researches of triple-negative breast cancer and esophageal squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-P990552A

Target:  

PAI-1 Integrin

Research Areas:  

Cancer

huATN-658 is an inhibitor that specifically targets the DIII domain of human urokinase plasminogen activator receptor (uPAR). huATN-658 neutralizes uPAR function by blocking the interaction between uPAR and integrins, without interfering with the binding of uPA or vitronectin to uPAR. huATN-658 inhibits the proliferation and invasion of breast cancer cells, slows the growth of primary breast tumors, reduces breast cancer-induced bone lesions and decreases osteoclast activity. huATN-658 also alters the gene expression of the TGF-β receptor complex signaling pathway. huATN-658 exerts synergistic anticancer effects when combined with Zoledronic Acid (HY-13777), and does not cause physiological or behavioral abnormalities in immunodeficient mice. huATN-658 can be used in research related to breast cancer, metastatic breast cancer and breast cancer-induced bone disease .
loading...
    loading...
Cat. No.: HY-P990643
Target:  

Integrin

Research Areas:  

Neurological Disease Cancer

OS-2966 is a humanized neutralizing monoclonal antibody (huIgG1κ) targeting human CD29 (β1 integrin/ITGB1). OS-2966 blocks integrin β1 signaling, inhibits tumor cell proliferation, invasion, migration and mesenchymal phenotype, and enhances the efficacy of oncolytic herpes simplex virus-1 (oHSV) and anti-angiogenic therapies. OS-2966 can be used in research related to triple-negative breast cancer, high-grade meningioma, glioblastoma and ovarian cancer .
loading...
    loading...
Cat. No.: HY-P10045
CAS No.: 1335046-19-9
Target:  

Integrin

Research Areas:  

Cardiovascular Disease

Integrin signaling inhibitor, mP13 is an inhibitor of integrin signaling. Integrin signaling inhibitor, mP13 inhibits inside-out and outside-in signaling, including fibrinogen binding, platelet adhesion, and clot retraction .
loading...
    loading...